Patients

TIF Webinar Fridays Are Back With A New Session on « Heart Disease In Thalassaemia »
Actualités

TIF Webinar Fridays Are Back With A New Session on « Heart Disease In Thalassaemia »

This Friday, 23 October 2020, at 15:00 EEST/13:00 BST, get ready to join Prof. Malcolm Walker and Dr. Dimitris Farmakis in our webinar on  »Heart Disease In Thalassaemia » for Patients/Parents,…
Thal e-Course Webinar Series: Iron Monitoring in Thalassaemia
Thal e-Course Webinars

Thal e-Course Webinar Series: Iron Monitoring in Thalassaemia

The effective management of iron overload and the importance of frequent monitoring of iron status in patients with thalassaemia were the focal points of the Thal e-Course Webinar Series’ 2nd…
Johnson & Johnson Pauses Clinical Trials For Its Covid-19 Vaccine Over Participant’s Illness
Actualités

Johnson & Johnson Pauses Clinical Trials For Its Covid-19 Vaccine Over Participant’s Illness

Johnson & Johnson has paused its Covid-19 vaccine trial due to an “unexplained illness” in a participant, the company confirmed yesterday evening. The pharmaceutical giant was unclear if the patient…
Hidden Victims Of The Pandemic: Blood Bank Stocks Run Low As India’s Healthcare System Buckles
Actualités

Hidden Victims Of The Pandemic: Blood Bank Stocks Run Low As India’s Healthcare System Buckles

As public healthcare resources are redirected to halt the spread of coronavirus, victims of other life-threatening diseases pay the ultimate price. This recent news story, published by The Telegraph, depicts…
Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
Actualités

Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease

Fulcrum Therapeutics, Inc.  a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that FTX-6058, its investigational treatment for sickle cell disease (SCD) and…
TIF Develops Mobile Application To Support Patients With Thalassaemia
Actualités

TIF Develops Mobile Application To Support Patients With Thalassaemia

As part of its enduring efforts to develop useful tools for individuals with thalassaemia and haemoglobin disorders worldwide, TIF will soon introduce a novel mobile health application, named ‘’THALIA Mobile…
Coming Up This Week:  »Iron Monitoring in Thalassaemia » Webinar for Patients
Actualités

Coming Up This Week:  »Iron Monitoring in Thalassaemia » Webinar for Patients

Although chronic blood transfusion regimens have added decades to the lives of patients with thalassaemia, clinicians are now faced with increasingly complicated management challenges. The devastating effect of the accumulated…
Gene Therapy LentiGlobin Granted Priority Medicines Designation for Sickle Cell Disease in the EU
Actualités

Gene Therapy LentiGlobin Granted Priority Medicines Designation for Sickle Cell Disease in the EU

Bluebird Bio’s investigational gene therapy LentiGlobin has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of sickle cell disease (SCD). Given to candidate therapies with promising clinical data for diseases of high…
Thal e-Course Webinar Series: Liver Disease in Thalassaemia
Thal e-Course Webinars

Thal e-Course Webinar Series: Liver Disease in Thalassaemia

Meeting your continuing educational needs on thalassaemia has never been easier! The 1st Webinar to inaugurate the TIF Thal e-Course Webinar Series for patients with thalassaemia has been successfully completed.…
Bouton retour en haut de la page